e-learning
resources
Vienna 2003
Sunday 28.09.2003
New aspects of community acquired pneumonia
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Effects of salmeterol on the ciliary beat in patients with community-acquired pneumonia
G. Piatti, U. Ambrosetti, M. Dal Sasso, P. Braga, C. Gambardella, L. Allegra (Milan, Italy)
Source:
Annual Congress 2003 - New aspects of community acquired pneumonia
Session:
New aspects of community acquired pneumonia
Session type:
Oral Presentation
Number:
136
Disease area:
Airway diseases, Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
G. Piatti, U. Ambrosetti, M. Dal Sasso, P. Braga, C. Gambardella, L. Allegra (Milan, Italy). Effects of salmeterol on the ciliary beat in patients with community-acquired pneumonia. Eur Respir J 2003; 22: Suppl. 45, 136
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Management of severe community acquired pneumonia – ERS guidelines
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Predictive indexes in prolonged weaning of mechanical ventilation due to tracheostomy in patients with COVID-19 pneumonia
Related content which might interest you:
Comparison of costs of community-acquired pneumonia (CAP) treatment at patients with and without bronchial obstruction
Source: Annual Congress 2011 - COPD management
Year: 2011
Heliox-therapy of patients with execerbation of COPD and community-acquired pneumonia
Source: Eur Respir J 2006; 28: Suppl. 50, 106s
Year: 2006
Effects of salmeterol on ciliary beat and mucus rheology in COPD patients
Source: Eur Respir J 2003; 22: Suppl. 45, 78s
Year: 2003
Low-dose corticosteroid use and mortality in severe community-acquired pneumonia patients
Source: Eur Respir J 2015; 45: 463-472
Year: 2015
Efficacy of corticosteroids in hospital treated community-acquired pneumonia
Source: Annual Congress 2012 - Clinical management of lung diseases: from bronchi to pleura
Year: 2012
Etiology pathogens structure in community-acquired pneumonias and COPD exacerbations
Source: Annual Congress 2011 - Role of infection in exacerbations of COPD
Year: 2011
COPD: what is the frequency and impact of community-acquired pneumonia?
Source: Annual Congress 2008 - Community-acquired pneumonia and COPD: what do we know?
Year: 2008
Analysis of therapy of community-acquired pneumonia (CAP) at the COPD patients
Source: Annual Congress 2011 - COPD management
Year: 2011
Impact of inhaled corticosteroid use on outcome in COPD patients admitted with pneumonia
Source: Eur Respir J 2011; 37: 36-41
Year: 2011
Penetration of moxifloxacin in bronchial secretions in hospitalized patients with acute exacerbation of COPD
Source: Annual Congress 2013 –Antibiotics, resistance and vaccines
Year: 2013
Low-dose corticosteroids during severe community-acquired pneumonia: end of the story
Source: Eur Respir J 2015; 45: 305-307
Year: 2015
Duration of antibiotic therapy in hospitalised patients with community-acquired pneumonia
Source: Eur Respir J 2010; 36: 128-134
Year: 2010
Peculiarities of community-acquired pneumonia in tobacco-smoking patients
Source: Annual Congress 2009 - Tobacco: from smoke to disease
Year: 2009
Efficacy and safety of levofloxacin treatment of community-acquired pneumonia in hospitalized patients
Source: Eur Respir J 2005; 26: Suppl. 49, 637s
Year: 2005
Delirium induced by clarithromycin in a patient with community-acquired pneumonia
Source: Eur Respir J 2006; 28: 671-672
Year: 2006
Are corticosteroids useful in community-acquired pneumonia?
Source: Annual Congress 2006 - Evaluation of risk factors in community-acquired pneumonia
Year: 2006
Antipyretic effect of dexamethasone in community-acquired pneumonia
Source: Eur Respir J 2015; 46: 570-573
Year: 2015
Enhanced neutrophil response in patients with chronic bronchitis and community-acquired pneumonia (CAP)
Source: Eur Respir J 2002; 20: Suppl. 38, 418s
Year: 2002
Cost of treatment failure in community-acquired pneumonia
Source: Eur Respir J 2007; 30: Suppl. 51, 195s
Year: 2007
Comparing pneumonia incidence in COPD patients treated with or without inhaled corticosteroid
Source: Virtual Congress 2021 – Inhaled treatments for COPD: real-world data
Year: 2021
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept